97% Institutional holdings. Zero splits. Let's just face it, there's management who give and management who take. Makes all the difference in the world.
>>DICE Therapeutics Inc. shares were up 51%, to $37.32, on Tuesday after the company reported positive topline data from its Phase 1 clinical trial of DC-806, an oral small molecule antagonist of the pro-inflammatory cytokine IL-17.
The stock hit its 52-week high of $45.99 earlier in the session, and is up 122% in the past three months.
The biopharmaceutical company said the trial was designed to generate safety and pharmacokinetic data in healthy volunteers as well as provide early clinical proof-of-concept in psoriasis patients.
DICE said it plans to advance DC-806 into a dose-ranging Phase 2b clinical trial in patients with moderate-to-severe psoriasis. The company plans to submit an investigational new-drug application with the U.S. Food and Drug Administration in the first half of 2023 and initiate Phase 2b development, it said.